Key result
A doubling in endogenous GLP-1 response to oral glucose was associated with a 1.17 mmHg lower central systolic blood pressure in individuals at risk of diabetes.
Why the study?
GLP-1 receptor agonists reduce blood pressure and CVD risk, but the association between endogenous GLP-1 responses to oral glucose and haemodynamic measures remained unclear.
Is greater endogenous GLP-1 response to oral glucose associated with lower central and peripheral blood pressures in individuals at risk of diabetes?
Cross-Sectional (n=837)
Yes
Is greater endogenous GLP-1 response to oral glucose associated with lower central and peripheral blood pressures in individuals at risk of diabetes?
Mean Difference: -1.17 (95% CI -2.07–-0.27)
p-value: p=0.011
Greater endogenous glucose-stimulated GLP-1 responses are associated with clinically relevant lower central and peripheral blood pressures, suggesting a physiological role of GLP-1 in cardiovascular regulation.
Greater endogenous GLP-1 responses were associated with lower BP; leaves open causal role in hypertension prevention.
BACKGROUND AND AIM: Cardiovascular diseases (CVDs) are globally the leading cause of death and hypertension is a significant risk factor. Treatment with glucagon-like peptide-1 (GLP-1) receptor agonists has been associated with decreases in blood pressure and CVD risk. Our aim was to investigate the association between endogenous GLP-1 responses to oral glucose and peripheral and central haemodynamic measures in a population at risk of diabetes and CVD. METHODS: , without antihypertensive treatment and known diabetes). All participants received an oral glucose tolerance test with measurements of GLP-1 at 0, 30 and 120 min. Aortic stiffness was assessed by pulse wave velocity (PWV). The associations between GLP-1 response and central and brachial blood pressure (BP) and PWV were assessed in linear regression models adjusting for age and sex. RESULTS: A greater GLP-1 response was associated with lower central systolic and diastolic BP of - 1.17 mmHg (95% confidence interval (CI) - 2.07 to - 0.27 mmHg, P = 0.011) and - 0.74 mmHg (95% CI - 1.29 to - 0.18 mmHg, P = 0.009), respectively, as well as lower brachial systolic and diastolic BP of - 1.27 mmHg (95% CI - 2.20 to - 0.33 mmHg, P = 0.008) and - 1.00 (95% CI - 1.56 to - 0.44 mmHg, P = 0.001), respectively. PWV was not associated with GLP-1 release (P = 0.3). Individuals with the greatest quartile of GLP-1 response had clinically relevant lower BP measures compared to individuals with the lowest quartile of GLP-1 response (central systolic BP: - 4.94 (95% CI - 8.56 to - 1.31) mmHg, central diastolic BP: - 3.05 (95% CI - 5.29 to - 0.80) mmHg, brachial systolic BP: - 5.18 (95% CI - 8.94 to - 1.42) mmHg, and brachial diastolic BP: - 2.96 (95% CI - 5.26 to - 0.67) mmHg). CONCLUSION: Greater glucose-stimulated GLP-1 responses were associated with clinically relevant lower central and peripheral blood pressures, consistent with beneficial effects on the cardiovascular system and reduced risk of CVD and mortality. Trial registration ClinicalTrials.gov Identifier: NCT00237549. Retrospectively registered 10 October 2005.
No takes yet. Share an insight, caveat, or question.
Lundgren et al. (2019) conducted a cross-sectional in At risk of diabetes and cardiovascular disease (n=837). Endogenous GLP-1 response to oral glucose vs. Lower endogenous GLP-1 response was evaluated on Central systolic blood pressure (MD -1.17 mmHg, 95% CI -2.07 to -0.27, p=0.011). A doubling in endogenous GLP-1 response to oral glucose was associated with a 1.17 mmHg lower central systolic blood pressure in individuals at risk of diabetes.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: